Amundi’s Arbutus Biopharma ABUS Stock Holding History

Amundi’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$57K	Hold	11,878	–	–	﹤0.01%	2046
2026 Q1	$53.5K	Hold	11,878	–	–	﹤0.01%	1979
2025 Q4	$57.1K	Buy	+11,878	New	+$53.4K	﹤0.01%	1827

Other funds holding ABUS

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Amundi's ABUS Position: Q2 2026 in Review

Amundi held its Arbutus Biopharma (ABUS) position steady in Q2 2026 at 11,878 shares worth $57K. The position accounts for ﹤0.01% of the portfolio, ranked #2046.

Amundi first reported a position in ABUS in Q4 2025 and has held it in 3 quarters since. The position peaked at $57.1K in Q4 2025. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

Amundi held 11,878 shares of Arbutus Biopharma worth $57K as of Q2 2026.
Amundi left its Arbutus Biopharma share count unchanged in Q2 2026.
Arbutus Biopharma made up ﹤0.01% of Amundi's portfolio in Q2 2026, its #2046 holding.
Amundi first reported a position in Arbutus Biopharma in Q4 2025 and has held it in 3 quarters since.
Amundi's Arbutus Biopharma position peaked at $57.1K in Q4 2025.
177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.